Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(Guselkumab + golimumab) by Johnson & Johnson for Psoriatic Arthritis: Likelihood of Approval
(Guselkumab + golimumab) is under clinical development by Johnson & Johnson and currently in Phase II for Psoriatic Arthritis. According...
(Guselkumab + golimumab) by Johnson & Johnson for Ulcerative Colitis: Likelihood of Approval
(Guselkumab + golimumab) is under clinical development by Johnson & Johnson and currently in Phase II for Ulcerative Colitis. According...
(Guselkumab + golimumab) by Johnson & Johnson for Crohn's Disease (Regional Enteritis): Likelihood of Approval
(Guselkumab + golimumab) is under clinical development by Johnson & Johnson and currently in Phase II for Crohn's Disease (Regional...